

Company Overview

Commonwealth Laboratories, Inc., founded in 2011, is a state and federally licensed clinical laboratory that specializes in a variety of methane and hydrogen breath tests, and now blood tests, that help diagnose multiple digestive disorders.

About Commonwealth Labs, Inc.



Commonwealth provides accurate results for their entire line of tests within 24 hours of specimen receipt. Each test is easy to use; patients can administer every breath test in the comfort of their own home. A prepaid shipping label is included, which enables the sample delivery at Commonwealth.

Research & Development

Commonwealth has most recently developed IBSchek™, a quick and reliable blood test that helps doctors diagnose Irritable Bowel Syndrome (IBS). IBSchek™ is based on the findings of Mark Pimentel, MD, which showed that anti-vinculin and anti-CdtB are effective biomarkers for the diagnosis of IBS. The test utilizes a proprietary, ELISA-based blood test, providing results within 24 hours of sample delivery. Its turnkey approach is office friendly and addresses the needs of IBS patients, either confirming or eliminating IBS as a cause of symptoms.



IBSchek™ tests for the presence of antibodies that are created by alterations in intestinal microbiota (microbes) resulting from acute gastroenteritis. It detects levels of an antibody to a toxin from gastroenteritis called CdtB (cytolethal distending toxin B), as well as vinculin, an antibody that forms against the body. While the test is more specific for anti-CdtB, the anti-vinculin component suggests that IBS may be an autoimmune disease. The two biomarkers are complimentary in further understanding IBS and together enable a differential diagnosis of IBS from other gastrointestinal diseases.

In the past, a diagnosis of IBS was one of exclusion, meaning a person was determined to have IBS only after testing excluded other disorders that could be causing the symptoms. IBSchek™ is a paradigm-shifting technology that will enable the diagnosis of IBS to become one of inclusion, potentially saving patients years of pain and frustration by getting them an accurate diagnosis and treatment faster. IBSchek™ was developed and validated at Commonwealth's corporate headquarters in Salem, Mass.

Products

In addition to IBSchek™ (available May 2015), Commonwealth currently offers kits to test for:

- Small Intestinal Bacterial Overgrowth (SIBO)
- Lactose, Fructose, and Sucrose Intolerance
- Helicobacter Pylori (H. Pylori)

Partnerships

In 2013, Commonwealth entered an exclusive licensing agreement with Cedars-Sinai in Los Angeles, California, for patents developed for diagnosing IBS and other disorders caused by SIBO.

Executives

Brian Strasnick, Chief Executive Officer

Craig Strasnick, Chief Operating Officer

Gray Rifkin, General Counsel and Director of Commercial Affairs